UK Community Advisory Board (UK-CAB)

UK-CAB 24 – BHIVA 2007 clinical audit – microbicides – PEPSE – PrEP – Pfizer

25 January 2008


09.00 – 09.30 Registration and welcome
09.30 – 10.00 UKCAB updates and conference feedback
10.00 – 10.45 BHIVA 2007 audit: treatment of naïve patients – Dr Hilary Curtis, BHIVA clinical audit co-ordinator
10.45 – 11.00 Break
11.00 – 11.15 Pfizer pre-meeting
11.15 – 12.30 Company meeting: Pfizer
12.30 – 14.00 Lunch
14.00 – 14.45 Campaigning for microbicides – Eunice Sinyemu, African and Minority Ethnic HIV Project and UK African Microbicides Working Group, Toju Cline-Cole, THT and UK African Microbicides Working Group
14.45 – 15.15 Promoting PEPSE: what is the role of HIV treatment advocates? – Elias Phiri, THT
15.15 – 15.30 Break
15.30 – 16.00 PrEP: pre-exposure prophylaxis – Gus Cairns, freelance journalist
16.00 – 16.30 AOB, next meeting etc

Background reading

BHIVA 2007 audit

Dr Hilary Curtis will present findings from treatment of BHIVA’s 2007 audit of treatment of naïve patients.

BHIVA clinical audit report 2006-7 PDF 108 Kb

BHIVA audit 2006-7: survey of patient assessment and monitoring of patients starting ART from naïve PDF 80 Kb

BHIVA audit 2006-7: cohort audit of patients starting ART from naïve PowerPoint 146 Kb

Patient organisations and ABPI code of practice

Background reading for the Pfizer pre-meeting – ABPI code of practice and the consultation from European Federation of Pharmaceutical Industries and Associations (EFPIA) regarding interactions with patient organisations.

Working consultatively Prescription Medicines Code of Practice Authority

Prescription Medicines Code of Practice Authority, 333 Kb

Pfizer – The drug development process

Pfizer representatives will present on the processes used in the search for new medicines.

Research and development at Pfizer Pfizer

Campaigning for microbicides

The word “microbicides” refers to a range of different products that share one common characteristic: the ability to prevent the sexual transmission of HIV and other sexually transmitted infections when applied topically. A microbicide could be produced in many forms, including gels, creams, suppositories, films, or as a sponge or ring that releases the active ingredient over time.

About microbicides Global Campaign for Microbicides

The Global Campaign for Microbicides is a broad-based, international effort to build support among policymakers, opinion leaders, and the general public for increased investment into microbicides and other user-controlled prevention methods.

Women, HIV and microbicides seminar report PDF George House Trust and UK African Microbicides Working Group, 210 Kb

Promoting PEPSE

BASSH guidelines for post-exposure prophylaxis after sexual exposure (PEPSE) to HIV includes a review of the current data to support the use of PEPSE.

UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure PDF BASSH, 180 Kb. This document includes a review of the current data to support the use of PEPSE.

PEP for sexual exposure to HIV doesn’t lead to more risky sex Aidsmap

Accessing post-exposure prophylaxis (PEP) after sexual risk: the experiences of homosexually active men in England International AIDS Society (IAS)

‘Well, you can do something about it, there’s PEP’ – HIV-positive gay men have role in telling partners about PEP Aidsmap

Pre-exposure prophylaxis

Pre-exposure prophylaxis (PrEP) – where ARVs are given before possible exposure to HIV – is the subject of current research.

The trials of tenfovir

Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PREP” trials PDF AIDS Vaccine Advocacy Coalition (AVAC), 640 Kb

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.